Document is current

Article History

Received: 6 August 2024

Accepted: 2 January 2025

First Online: 8 February 2025

Competing interests

: B.B. declares having received fees for medical education in a consulting or advisory role with Lilly, Pfizer, MSD, Pierr Fabre, Astra Zeneca, and Gilead; participated in a speakers’ bureau with Roche, MSD, Daichii, Sankio Astra Zeneca, Novartis, Lilly, Gilead, Seagen; travel accommodation by Pfizer and Gilead. Y.J.G. declares having received speakers´ honoraria from Roche, Novartis, Lilly, Daichii, and AstraZeneca; travel and training grants from Roche, Novartis, Pfizer, Daichii, Gilead, and Lilly. A.F.A. declares Honoraria or consultation fees from GSK, MSD, AstraZeneca, Pharma & Go, EISAI, Lilly, Pfizer, Novartis, and Pierre Fabre; travel/accommodation expenses from GSK, MSD, AstraZeneca, and Pfizer; speakers bureau participation with GSK, MSD, AstraZeneca, EISAI, Novartis and Pierre Fabre. F.M. declares consulting/advisory role with Novartis, Pfizer, AstraZeneca, MSD, Daiichi Sankyo, and Seagen; speakers’ bureau from Pfizer and Novartis; research funding from Pfizer; travel/accommodations expenses by Pfizer, Novartis and Gilead. M.H.L.-C. declares having received speaker honoraria from Daichii, Novartis & Pierre Fabre; and travel and training grants from Roche & Novartis. I.B. declares having research funding from Agendia, AstraZeneca, Lilly, Pfizer, and Roche; honoraria as a medical monitor from Medical Scientia Innovation Research (MEDSIR); honoraria and advisor collaboration from AstraZeneca, Bristol-Myers Squibb, Celgene, Daiichi-Sankyo, Eisai, Gilead, Grünenthal, GSK, Jazz Pharmaceutical, Lilly, MSD, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen and Veracyte; travel and meeting attendance grants from AstraZeneca, Bristol-Myers Squibb, Daiichi-Sankyo, Gilead, Lilly, Novartis, Pfizer, Pierre-Fabre and Roche. A.G.-Z. declares institutional grant from Pfizer; advisory role honoraria from AstraZeneca, Novartis, MSD, Pierre-Fabre, Exact Science, Menarini-Stemline and Daichy Sankyo; travel grants from Roche, Novartis, Pfizer, Gilead and Pierre Fabre; speaker Bureau/Expert testimony with Roche, AstraZeneca, Daichi-Sankyo, Novartis, MSD, Pfizer and Menarini-Stemline. J.H.-R. declares having received research grants from Roche and Pfizer; consulting/advisory fees from AstraZeneca, Amgen, Roche/Genentech, Novartis, Eli Lilly, and Pfizer; speakers’ honoraria from AstraZeneca, Lilly, Amgen, Roche/Genentech, Novartis, and Pfizer. All remaining authors have declared no conflicts of interest.